BioXcel Therapeutics (NASDAQ:BTAI) is a biopharmaceutical company focused on harnessing artificial intelligence to advance the drug discovery and development process. The company's primary mission is to utilize its proprietary AI platform, which analyzes millions of data points to identify and develop novel therapeutics for the treatment of disorders in the fields of neuroscience and immuno-oncology. BioXcel Therapeutics is dedicated to addressing unmet medical needs, aiming to improve outcomes for patients through innovative therapies. Its projects include a diverse pipeline of drugs in various stages of development, targeting conditions such as acute treatment of agitation in patients with schizophrenia and bipolar disorder, as well as advanced solid tumors. The company's strategic objectives include advancing its clinical programs to commercialization, expanding its drug pipeline, and establishing collaborations to leverage its AI platform's full potential in drug discovery and development.